Pieris Pharmaceuticals Files 8-K
Ticker: PVLA · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1583648
| Field | Detail |
|---|---|
| Company | Pieris Pharmaceuticals, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $26.4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
Pieris Pharma dropped an 8-K on 3/27 detailing financials and other events.
AI Summary
Pieris Pharmaceuticals, Inc. filed an 8-K on March 27, 2024, reporting on its results of operations, other events, and financial statements. The filing details the company's financial condition and significant corporate events.
Why It Matters
This 8-K filing provides crucial updates on Pieris Pharmaceuticals' financial performance and operational events, which are important for investors to assess the company's current status.
Risk Assessment
Risk Level: medium — 8-K filings can contain a wide range of information, from routine updates to significant events, making the risk level dependent on the specific details within the report.
Key Players & Entities
- PIERIS PHARMACEUTICALS, INC. (company) — Registrant
- March 27, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- 225 Franklin Street, 26th Floor (address) — Principal Executive Offices
- Boston, MA 02110 (address) — Principal Executive Offices
- 857-246-8998 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Pieris Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Pieris Pharmaceuticals' results of operations and financial condition, as well as other events and financial statements.
On what date was this 8-K filed?
This 8-K was filed on March 27, 2024.
In which U.S. state is Pieris Pharmaceuticals incorporated?
Pieris Pharmaceuticals, Inc. is incorporated in Nevada.
What is the principal executive office address for Pieris Pharmaceuticals?
The principal executive office address is 225 Franklin Street, 26th Floor, Boston, MA 02110.
What is the telephone number listed for Pieris Pharmaceuticals?
The telephone number listed for Pieris Pharmaceuticals is 857-246-8998.
Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-03-27 08:00:14
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value per share PIRS The Nasdaq
- $26.4 million — s of December 31, 2023, the Company had $26.4 million in cash and investments. The Company re
Filing Documents
- pirs20240323_8k.htm (8-K) — 31KB
- ex_645776.htm (EX-99.1) — 23KB
- ex_645776img001.jpg (GRAPHIC) — 2KB
- 0001437749-24-009491.txt ( ) — 198KB
- pirs-20240327.xsd (EX-101.SCH) — 3KB
- pirs-20240327_def.xml (EX-101.DEF) — 12KB
- pirs-20240327_lab.xml (EX-101.LAB) — 15KB
- pirs-20240327_pre.xml (EX-101.PRE) — 12KB
- pirs20240323_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 27, 2024, Pieris Pharmaceuticals, Inc. (the "Company") issued a press release in which it announced a strategy for the Company to maximize its ability to capture the potential milestones from certain existing licensing and collaboration agreements, while maintaining the capability to consider other strategic opportunities that it believes may increase stockholder value. In the press release, the Company announced that as of December 31, 2023, the Company had $26.4 million in cash and investments. The Company remains committed to obtaining value for its products in prior development, including cinrebafusp alfa, as well as its proprietary platform capabilities through, for example, out-licensing or sale. The cash and investments information above is based on preliminary, unaudited information and management estimates for the year ended December 31, 2023, is not a comprehensive statement of the Company's financial results as of and for the year ended December 31, 2023 and is subject to completion of the Company's financial closing procedures and may change. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate. The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including the estimate of the Company's cash and investments as of December 31, 2023 set forth in the press release in Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. The information in the press release attached as Exhibit 99.1 to this report, except for the estimate of the Company's cash and investments as of December 31, 2023 as set forth in the press release, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release, dated March 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PIERIS PHARMACEUTICALS, INC. Dated: March 27, 2024 /s/ Tom Bures Tom Bures Chief Financial Officer